Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales
China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for...
Company
Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases
Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...
eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership
Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million...
Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial
Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...
Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...
NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall
The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...
Biocytogen and Merck KGaA Ink Global Deal for RenMice Platform Licensing
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global...
3SBio Inc. Reports H1 2020 Revenue of RMB 3.091B, Net Profit Up 6.19%
China-based 3SBio Inc. (HKG: 1530) reported its H1 2020 financial results, with revenue of RMB...
Betta Pharmaceuticals’ H1 2022 Revenues Rise 8.5% on Drug Sales Growth
China’s Betta Pharmaceuticals (SHE: 300558) reported RMB 1.25 billion (USD 182.5 million) in revenue for...
Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers
Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been...
CSPC Pharmaceutical’s SYS6006 mRNA Vaccine Shows Strong Safety and Efficacy in Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA...
SinoMab Bioscience’s SN1011 Gets NMPA Nod for NMOSD Trial
Hong Kong-based SinoMab Bioscience Ltd (HKG: 3681) has received approval from the National Medical Products...
Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...
Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors
Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...
BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...
Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...
Lee’s Pharma Expands Global Rights to Windtree’s KL4 Surfactant Products
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree...
Genetron Holdings Receives Buyout Offer from CEO Wang Sizhen at USD 1.36 per ADS
Beijing-based precision oncology firm Genetron Holdings Ltd announced receipt of a buyout and take-private offer...
Ascletis Pharma’s H1 2022 Revenue Rises 4.8% on R&D and Product Sales Growth
Ascletis Pharma Inc. (HKG: 1672) reported RMB 38.2 million (USD 5.96 million) in revenue for...
Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review
The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is...